Q-omics provides the consensus-scored CD22 profile across patient tissues and cancer cell-line models. CD22 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CD22 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, CD22 RNA expression shows 21,636 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, BLCA, and LSCC as cancer lineages where CD22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD22 survival associations across molecular data types. CD22 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD22 RNA expression–survival associations across cancer types. High CD22 expression shows unfavorable associations in KIRP, but favorable associations in HNSC, BRCA, LUAD, ESCA and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CD22 RNA expression.
This table summarizes CD22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CD22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD22 shows lower tumor expression in BLCA, COAD, UCEC and LUSC and higher tumor expression in KIRC and BRCA. The BLCA box plot shows higher CD22 RNA expression in normal versus tumor tissue (log2 FC = −1.422, t-test p = .001).
This table shows molecular features associated with CD22 in patient tissues and cancer cell lines. In patient samples, CD22 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CD22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
